PDF(1094 KB)
Effect of over-expression of NDRG1 on resistance of castration-resistant prostate cancer resistant cell line C4-2/ENZA and its mechanism
Ying ZHANG,Zhaohui WAN,Xianxun JIANG
PDF(1094 KB)
PDF(1094 KB)
Effect of over-expression of NDRG1 on resistance of castration-resistant prostate cancer resistant cell line C4-2/ENZA and its mechanism
Objective To discuss the effect of N-myc downstream-regulated gene 1 (NDRG1) on the enzalutamide (ENZA) resistance in the castration-resistant prostate cancer (CRPC), and to clarify its mechanism. Methods The human CRPC C4-2 cells and ENZA-resistant strain C4-2/ENZA cells were cultured in vitro. The expression levels of NDRG1 mRNA in the C4-2/ENZA cells and their parental C4-2 cells were detected by real-time fluorescence quantitative PCR (RT-qPCR) method. The expression levels of NDRG1, androgen receptor (AR), and prostate-specific antigen (PSA) proteins in the cells were detected by Western blotting method to verify the transfection efficiency of the cells. The C4-2/ENZA cells were divided into blank group (normally cultured without treatment), negative control lentivirus (Lv-NC) group (transfected with Lv-NC), Lv-NDRG1 group (transfected with Lv-NDRG1), Lv-NC+ENZA group (transfected with Lv-NC followed by ENZA treatment), Lv-NDRG1+ENZA group (transfected with Lv-NDRG1 followed by ENZA treatment), Lv-NDRG1+epidermal growth factor (EGF) group (transfected with Lv-NDRG1 followed by EGF treatment), and Lv-NDRG1+EGF+ENZA group (transfected with Lv-NDRG1 followed by EGF and ENZA treatment). The half-maximal inhibitory concentration (IC50), resistance index (RI), and proliferation activity of the cells were detected by MTT assay;the apoptotic rates of the cells in various groups were detected by flow cytometry; RT-qPCR method was used to detect the expression levels of NDRG1 mRNA in the cells in various groups; Western blotting method was used to detect the expression levels of NDRG1, AR, phosphorylated AR at serine213 (p-ARSer213), phosphorylated AR at serine81 (p-ARSer81), and PSA proteins in the cells in various groups. Results Compared with C4-2 cells, the expression levels of NDRG1 mRNA and protein in the C4-2/ENZA cells were significantly decreased (P<0.01) and the expression levels of AR and PSA proteins were increased (P<0.01), indicating low expression of NDRG1 in the ENZA-resistant C4-2/ENZA strain. Compared with Lv-NC group, the expression levels of NDRG1 mRNA and protein in the cells in Lv-NDRG1 group were significantly increased (P<0.01), indicating the successful construction of an NDRG1 gene over-expression strain of C4-2/ENZA resistant cells. The MTT assay results showed that compared with the C4-2 cells,the IC50 of the C4-2/ENZA cells was increased (P<0.01) and the RI was 17.78; compared with Lv-NC group, the IC50 of the C4-2/ENZA cells in Lv-NDRG1 group was decreased (P<0.01). After 24 h of EGF treatment, compared with Lv-NC group, the IC50 of the C4-2/ENZA cells in Lv-NC+EGF group was significantly increased (P<0.01); compared with Lv-NDRG1 group, the IC50 of the C4-2/ENZA cells in Lv-NDRG1+EGF group was increased (P<0.01). Compared with before ENZA treatment, after 24 h of ENZA treatment, the proliferation activities of C4-2 and C4-2/ENZA cells were gradually decreased (F=223.80, P<0.01; F=81.46, P<0.01). Compared with Lv-NC group, the proliferation activity in the C4-2/ENZA cells in Lv-NDRG1 group after 24 h of ENZA treatment was significantly decreased (P<0.01). After 24 h of EGF treatment, compared with Lv-NC group, the proliferation activity of the C4-2/ENZA cells in Lv-NC+EGF group was significantly increased (P<0.01), while the the proliferation activity of the C4-2/ENZA cells in Lv-NDRG1+EGF group was significantly decreased (P<0.01). The chosen concentration and treatment duration for further testing were 10 000 μmol·L-1 ENZA and the intervention time was 24 h. The flow cytometry results showed that after 24 h of ENZA treatment, compared with Lv-NC group, the apoptotic rate of the cells in Lv-NDRG1 group was significantly increased (P<0.01); compared with Lv-NC+ENZA group,the apoptotic rate of the cells in Lv-NDRG1+ENZA group was significantly increased (P<0.01). After 24 h of EGF treatment, compared with Lv-NDRG1 group, the apoptotic rate of the cells in Lv-NDRG1+EGF group was significantly decreased (P<0.01), while the apoptotic rate of the cells in Lv-NDRG1+ENZA group was significantly increased (P<0.01); compared with Lv-NDRG1+ENZA group, the apoptotic rate of the cells in Lv-NDRG1+EGF+ENZA group was significantly decreased (P<0.01). The Western blotting results showed that after 24 h of ENZA treatment, compared with Lv-NC group, the expression levels of AR and PSA proteins and the ratio of p-ARSer213/AR and p-ARSer81/AR in the cells in Lv-NDRG1 group were significantly decreased (P<0.05 or P<0.01). After 24 h of EGF treatment, compared with Lv-NC group, the expression levels of AR and PSA proteins and the ratio of p-ARSer213/AR and p-ARSer81/AR in the cells in Lv-NC+EGF group were significantly increased (P<0.05 or P<0.01); compared with Lv-NDRG1 group, the expression levels of AR and PSA proteins and the ratio of p-ARSer213/AR and p-ARSer81/AR in the cells in Lv-NDRG1+EGF group were significantly increased (P<0.01). Conclusion Over-expression of NDRG1 can reduce the resistance of CRPC to ENZA, and its mechanism may be related to the inhibition of AR signaling.
Castration-resistant prostate cancer / N-myc downstream regulatory gene 1 / Enzalumide / Drug resistance / Androgen receptor
R737.25
| 1 | SEKHOACHA M, RIET K, MOTLOUNG P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches[J]. Molecules, 2022, 27(17): 5730. |
| 2 | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. |
| 3 | LIU J Z, DONG L, ZHU Y J, et al. Prostate cancer treatment - China’s perspective[J]. Cancer Lett, 2022, 550: 215927. |
| 4 | RITCH C, COOKSON M. Recent trends in the management of advanced prostate cancer[J]. F1000Res, 2018, 7.DOI:10.12688/f1000vesearch.15382.1 . |
| 5 | HE Y X, SHEN H, JI Y Z, et al. N-myc downstream regulated gene 1 inhibition of tumor progression in Caco2 cells[J]. World J Gastrointest Oncol, 2022, 14(12): 2313-2328. |
| 6 | VILLODRE E S, HU X D, ECKHARDT B L, et al. NDRG1 in aggressive breast cancer progression and brain metastasis[J]. J Natl Cancer Inst, 2022, 114(4): 579-591. |
| 7 | MAO M S, JIA Y L, CHEN Y X, et al. HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer[J]. Cell Death Dis, 2022, 13(4): 396. |
| 8 | LIM S C, GELETA B, MALEKI S, et al. The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer[J]. J Biol Chem, 2021, 297(6): 101414. |
| 9 | 郭晓波, 李 岗, 赵宇峰, 等. 长非编码RNA linc00641通过调节miR-362-5p/NDRG1逆转前列腺癌细胞多西他赛耐药的研究[J]. 沈阳药科大学学报, 2022, 39(6): 703-708. |
| 10 | 杨嘉昕, 夏 僮, 周驷杰, 等. 双氢青蒿素对前列腺癌PC-3 细胞自噬的诱导作用及其机制[J]. 解放军医学杂志, 2023, 48(6): 676-685. |
| 11 | 李 芳, 蒋妮谚含, 柳文洁, 等. 肿瘤耐药发生机制的研究进展[J]. 肿瘤药学, 2018, 8(3): 307-312. |
| 12 | NGUYEN D T, YANG W, RENGANATHAN A, et al. Acetylated HOXB13 regulated super enhancer genes define therapeutic vulnerabilities of castration-resistant prostate cancer[J]. Clin Cancer Res, 2022, 28(18): 4131-4145. |
| 13 | DUTTA S, POLAVARAM N S, ISLAM R, et al. Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer[J]. Oncogene, 2022, 41(30): 3747-3760. |
| 14 | CHEN X, YANG G, LIU M, et al. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/androgen receptor signaling pathway[J]. Biochem Biophys Res Commun, 2022, 613: 53-60. |
| 15 | DU Z B, CHEN X B, ZHU P Y, et al. SOX8 knockdown overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting the Notch signaling pathway[J]. Biomed Res Int, 2022, 2022: 9235837. |
| 16 | 王 蓓, 代聪伟, 李 娜, 等. 上调NDRG1基因对人卵巢癌OVCAR3细胞周期和凋亡的影响[J]. 中国老年学杂志, 2021, 41(14): 3045-3049. |
| 17 | 崔 喆, 商 震, 谷 乐, 等. 上调NDRG1表达降低奥沙利铂耐药结肠癌细胞的存活率[J]. 实用药物与临床, 2020, 23(4): 289-293. |
| 18 | YANG G, HUANG L, JIA H T, et al. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer[J]. Oncogene, 2021, 40(41): 5993-6006. |
| 19 | ANESTIS A, ZOI I, PAPAVASSILIOU A G, et al. Androgen receptor in breast cancer-clinical and preclinical research insights[J]. Molecules, 2020, 25(2): 358. |
| 20 | PLATA BELLO A, TAMAYO JOVER M A, GUTIERREZ NICOLAS F, et al. Biomarkers for characterization and therapeutic orientation in castration-resistant prostate cancer[J]. Arch Esp Urol, 2022, 75(2): 195-202. |
| 21 | KHAN A, MAO Y S, TAHREEM S, et al. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients[J]. Int J Biol Macromol, 2022, 218: 856-865. |
| 22 | 孙 红, 侯佳林, 蔡加琴, 等. SUMO E3连接酶介导雄激素受体的转录促进乳腺癌他莫昔芬耐药[J]. 中国临床药理学与治疗学, 2021, 26(3): 285-291. |
| 23 | GHILDIYAL R, SAWANT M, RENGANATHAN A, et al. Loss of long noncoding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance[J]. Cancer Res, 2022, 82(1): 155-168. |
| 24 | BONACCORSI L, MURATORI M, CARLONI V, et al. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells[J]. Steroids, 2004, 69(8/9): 549-552. |
| 25 | SHORNING B Y, DASS M S, SMALLEY M J, et al. The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling[J]. Int J Mol Sci, 2020, 21(12): 4507. |
| 26 | HSIEH T F, CHEN C C, MA W L, et al. Epidermal growth factor enhances androgen receptor-mediated bladder cancer progression and invasion via potentiation of AR transactivation[J]. Oncol Rep, 2013, 30(6): 2917-2922. |
/
| 〈 |
|
〉 |